Search Results
Sep 03, 2026, 09:03 ET MasterClass Launches Understanding GLP-1s and Weight Loss, the Guidance That Should Come With Every GLP-1 Prescription¹
world's best, today announced the launch of Understanding GLP-1s and Weight Loss, taught by Dr. Rocio Salas-Whalen, an endocrinologist and obesity medicine specialist who has spent more than 16 years treating patients with GLP-1 therapies and was among the earliest adopters of these medications
More news about: MasterClass
Sep 03, 2026, 06:11 ET Some Hair Loss in Men Is Linked to Use of Weight Loss Drugs
the study focused on the GLP1R gene, which naturally increases the body's levels of glucagon-like peptide-1 (GLP-1) receptor proteins, and used it as an indicator of GLP-1 agonist activity. More GLP1R activity means there are more GLP-1 receptor proteins. The researchers
More news about: NYU Langone Health System
Sep 03, 2026, 06:00 ET Superluminal Medicines Announces Oversubscribed $60 Million Series B Financing to Advance Lead Program in Rare Genetic Forms of Obesity into the Clinic
program may have future applications in rare diseases such as Prader-Willi syndrome, as well as in the broader population in combination with GLP-1 therapies. Superluminal's approach is designed to maximize therapeutic activity while minimizing side effects by activating only the signaling pathways
More news about: Superluminal Medicines
Sep 03, 2026, 05:37 ET Gan & Lee and Menarini Group Partner to Advance Bofanglutide in Europe
once-weekly GLP-1 RAs. The pivotal Phase 3 study in China and the Phase 2 study in the United States for weight management in adults with obesity or overweight both met their primary endpoints, demonstrating weight-loss efficacy and consistent tolerability profile with other GLP-1RA class therapies. Gan
More news about: Menarini Industrie Farmaceutiche Riunite
Sep 02, 2026, 16:05 ET Viking Therapeutics to Participate at Upcoming Investor Conferences
achieve meaningful, lasting health improvements by treating obesity first. The company's lead program, VK2735, is a dual glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist in development in both subcutaneous and oral formulations for obesity.
More news about: Viking Therapeutics, Inc.
Sep 02, 2026, 10:30 ET Biosimilars Market worth $70.79 billion by 2036 - Exclusive Report by MarketsandMarkets™
GLP-1 Agonists Market by Product (Ozempic, Wegovy, Mounjaro), Molecule (semaglutide, tirzepatide), Type (Patented, Biosimilars), Format (Single dose,
More news about: MarketsandMarkets
Sep 02, 2026, 10:12 ET My Adult Doctor™ Launches Nationwide Virtual Healthcare Platform Expanding 24/7 Urgent Care, Primary Care, Wellness, and Advanced Digital and AI Health Services Across All 50 States, Puerto Rico, and Guam
eliminates unnecessary barriers between patients and providers.My Adult Doctor will be the first and only 24/7 telehealth service that offers GLP and Peptide products, and has fully Board-Certified Physicians providing the care that is needed for either urgent or primary care.Through a secure
More news about: QC Healthcare
Sep 02, 2026, 10:00 ET OAC Calls on PepsiCo to Keep Obesity Treatment Coverage for Employees
added protein and fiber specifically with GLP-1 consumers in mind, including Propel Clear Protein, which PepsiCo CEO Ramon Laguarta has said is targeted to GLP-1 medication users.PepsiCo should not view people using GLP-1s as consumers worth investing in while making
More news about: Obesity Action Coalition
Sep 02, 2026, 09:09 ET /C O R R E C T I O N -- Jarrow Formulas/
from every gram they already consume.* Jarrow Gut & Protein Optimizer is great for those prioritizing their protein intake, including those using GLP-1s.*The product's formula combines Mycosha™, a clinically studied probiotic shown to support protein absorption and a healthy gut microbiome, with
More news about: Jarrow Formulas
Sep 01, 2026, 11:37 ET A Wave of Weight-Loss Drugs Is Quietly Creating a Multi-Billion-Dollar Opportunity That Aesthetic Medicine Is Racing to Capture
from surgery toward faster, lower-risk treatments. Now a powerful new catalyst has arrived from an unexpected direction, the explosion in GLP-1 weight-loss drugs, which is reshaping demand across the entire aesthetics landscape. Active companies from around the markets with current developments
More news about: Equity Insider
Sep 01, 2026, 11:15 ET New Survey: Consumers Using GLP-1 Medications Are Rethinking What Makes a Meal Worthwhile
84% of GLP-1 users say it is important that foods help them feel full or satisfied, while 81% say high-protein foods are important when deciding what to buy.Those priorities are translating into measurable changes in the grocery cart. Since starting GLP-1 medications:Since
More news about: National Frozen & Refrigerated Foods Association
Sep 01, 2026, 10:00 ET OrangeTwist National Med‑Spa Expands Its Skin‑Tightening Portfolio With the Launch of Density, a Needle‑Free Dual RF Technology
to strengthen the skin's foundation and improve overall resilience. As more clients navigate skin laxity linked to rapid weight loss from GLP-1 medications, along with the visible effects of "tech neck" from daily screen time, these treatments deliver a timely, effective solution to address
More news about: OrangeTwist
Sep 01, 2026, 09:07 ET Lift Procedures Led Growth as Demand for Restoration Drove Plastic Surgery in 2025, New ASPS Report Reveals
revision, resulting in 6 percent year-over-year growth.New data this year explores patient motivation, a rise in consultations related to GLP-1 weight loss and breast implant size preference. According to ASPS Member Surgeons, restoration following life changes such as pregnancy, aging and
More news about: American Society of Plastic Surgeons
Sep 01, 2026, 08:52 ET PCOS Challenge and Brigham and Women's Hospital Unite Patients, Experts and Policymakers to Accelerate Progress in PCOS/PMOS
people affected by PCOS/PMOS."The full-day program will address evidence-based approaches to diagnosis, treatment, and management; nutrition; GLP-1s and other medications; metabolic, reproductive, and mental health; care across the lifespan; research and treatment development. The program will
More news about: PCOS Challenge: The National Polycystic Ovary Syndrome Association
Sep 01, 2026, 08:38 ET Pure Genius Protein Launches Protein + Fiber Shots To Fill Nutrition Gap
zero sugar and zero fat. Built for the people who have the hardest time hitting nutrition goals in the first place - busy parents, people on GLP-1 medications eating far less, and older adults whose appetite has dropped, it requires no prep and delivers a light, juice-like texture with no grit,
More news about: Pure Genius Protein
Sep 01, 2026, 08:04 ET SHARx Urges HR and CFO Leaders to Rethink the True Cost of Pharmacy Benefits
that CHROs and CFOs review total pharmacy spend, year-over-year trend, forecast variance, employer and employee cost share, specialty and GLP-1 exposure, high-cost claimant concentration, prescription abandonment, member complaints and HR escalation volume, alongside recruitment, retention,
More news about: SHARx
Sep 01, 2026, 07:00 ET RedHill Announces Transformational Acquisition of Commercialization Rights to Ferring's Rebyota® and Clenpiq®
study in prostate cancer in combination with darolutamide; (ii) RHB-102 (Bekinda), with a planned Phase 2 proof-of-concept study for GLP-1/GIP receptor agonist-associated GI intolerance, positive results from a U.S. Phase 3 study for acute gastroenteritis and gastritis, positive results
More news about: RedHill Biopharma Ltd.
Sep 01, 2026, 06:00 ET U.S. News & World Report Survey: Health Experts Rank Core Lifestyle Habits Ahead of Biohacks for Longevity
longevity.Accelerated Muscle Loss in GLP-1 Users: Roughly three in four (76%) surveyed experts agreed or strongly agreed that accelerated muscle loss is a severe health threat for individuals using GLP-1 medications.Social Isolation as the Top Aging
More news about: U.S. News & World Report, L.P.
Sep 01, 2026, 05:00 ET Abacus Health Solutions Reports Long-Term Weight Loss Maintenance Outcomes, Addressing a Critical Evidence Gap in Obesity Care
common, long-term maintenance data remains scarce. Most new research is showing that participants and GLP-1 utilizers quickly regain most of the weight after discontinuing GLP-1 medication therapy.
More news about: Abacus Health Solutions
Aug 31, 2026, 22:25 ET Hydreight Reports Record Q2 2026 Revenue of $28.0 Million, Net Income of $2.5 Million and Adjusted EBITDA of $3.2 Million
compliantly. The platform is designed to help businesses launch direct-to-consumer healthcare brands across all 50 states.Offerings include GLP-1s, peptides, personalized healthcare treatments, sermorelin, testosterone replacement therapy ("TRT"), hair loss, skincare, sexual health and other healthcare
More news about: Hydreight Technologies Inc.
Aug 31, 2026, 09:00 ET Amai Proteins' sweelin® Approved for Sale in Israel, Opening the Market to a New Generation of Reduced-Sugar Food and Beverage Products
significantly reduce sugar or other conventional sweeteners, while maintaining excellent taste and aligning with growing demand for clean-label and GLP-1 friendly products.A New Tool for Product InnovationThe approval gives Israeli food and beverage manufacturers immediate access
More news about: Amai Proteins
Aug 31, 2026, 07:00 ET RedHill Divests Talicia® to Apotex for $18 Million Cash Upfront Plus Milestones to Fuel Strategic Growth Opportunities
Phase 2/3 program for hospitalized COVID-19; (ii) RHB-102 (Bekinda®), with a planned Phase 2 proof-of-concept study for GLP-1/GIP receptor agonist-associated GI intolerance, positive results from a U.S. Phase 3 study for acute gastroenteritis and gastritis, positive results
More news about: RedHill Biopharma Ltd.
Aug 31, 2026, 07:00 ET RedHill Divests Talicia® to Apotex for $18 Million Cash Upfront Plus Milestones to Fuel Strategic Growth Opportunities
Phase 2/3 program for hospitalized COVID-19; (ii) RHB-102 (Bekinda®), with a planned Phase 2 proof-of-concept study for GLP-1/GIP receptor agonist-associated GI intolerance, positive results from a U.S. Phase 3 study for acute gastroenteritis and gastritis, positive results
More news about: RedHill Biopharma Ltd.
Aug 31, 2026, 07:00 ET New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together showed improved and durable efficacy at one year in adults with psoriatic disease and obesity
psoriatic arthritis who also have obesity or overweight. Zepbound is the only FDA-approved dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist obesity management medication.Detailed 52-week results from TOGETHER-PsO and TOGETHER-PsA will be presented
More news about: Eli Lilly and Company
Aug 31, 2026, 01:00 ET Samsung Biologics publishes prospectus for PolyPeptide public tender offer
broad portfolio reflects the opportunities in drug therapies across areas and with significant exposure to metabolic diseases, including GLP-1. Dating back to 1952, PolyPeptide today runs a global network of six GMP-certified facilities in Europe, the U.S., and India. PolyPeptide's shares
More news about: Samsung Biologics